Karen Sims - 10 Jul 2023 Form 3 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Chief Medical Officer
Signature
/s/ David C. Hastings as attorney-in-fact for Karen Sims
Issuer symbol
ABUS
Transactions as of
10 Jul 2023
Net transactions value
$0
Form type
3
Filing time
12 Jul 2023, 16:48:48 UTC
Next filing
05 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABUS Common Shares 28,900 10 Jul 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABUS Stock Option (Right to Buy) 10 Jul 2023 Common Shares 15,000 $3.55 Direct F2
holding ABUS Stock Option (Right to Buy) 10 Jul 2023 Common Shares 25,500 $5.20 Direct F3
holding ABUS Stock Option (Right to Buy) 10 Jul 2023 Common Shares 28,000 $4.57 Direct F4
holding ABUS Stock Option (Right to Buy) 10 Jul 2023 Common Shares 39,900 $3.35 Direct F5
holding ABUS Stock Option (Right to Buy) 10 Jul 2023 Common Shares 39,900 $4.33 Direct F6
holding ABUS Stock Option (Right to Buy) 10 Jul 2023 Common Shares 82,460 $2.81 Direct F7
holding ABUS Stock Option (Right to Buy) 10 Jul 2023 Common Shares 57,800 $2.90 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the February 1, 2023 grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2 The option is fully vested as of June 21, 2020.
F3 This option is fully vested as of April 16, 2021.
F4 This option is fully vested as of March 1, 2022.
F5 This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 17, 2020 grant date, subject to the Reporting Person's continuous service as of each vesting date.
F6 This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 13, 2021 grant date, subject to the Reporting Person's continuous service as of each vesting date.
F7 This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the January 20, 2022 grant date, subject to the Reporting Person's continuous service as of each vesting date.
F8 This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 1, 2023 grant date, subject to the Reporting Person's continuous service as of each vesting date.

Remarks:

Exhibit 24: Power of Attorney